2-(3-cyano-1-cyclobutyl-5-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl)-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyrimidine-5-sulfonamide | 1247931-43-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-(3-cyano-1-cyclobutyl-5-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl)-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyrimidine-5-sulfonamide
• 英文别名: 2-(3-cyano-1-cyclobutyl-5-methyl-pyrrolo[2,3-b]pyridin-2-yl)-N-[(1S)-2,2,2-trifluoro-1-methyl-ethyl]pyrimidine-5-sulfonamide；2-(3-cyano-1-cyclobutyl-5-methylpyrrolo[2,3-b]pyridin-2-yl)-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyrimidine-5-sulfonamide
• CAS: 1247931-43-6
• 化学式: C₂₀H₁₉F₃N₆O₂S
• 分子量: 464.471
• InChiKey: NUGWSFSCVNUAFL-LBPRGKRZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  32
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  122
• 氢给体数：
  1
• 氢受体数：
  10

文献信息

• COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT
  申请人：Maccoss Malcolm

  公开号：US20120135999A1

  公开（公告）日：2012-05-31

  The present invention is directed to compounds and forms and pharmaceutical compositions thereof useful for treating a viral infection, or for affecting viral activity by modulating viral replication.

  本发明涉及化合物及其形式和制药组合物，可用于治疗病毒感染，或通过调节病毒复制来影响病毒活性。
• COMBINATIONS OF A HCV INHIBITOR SUCH AS BICYCLIC PYRROLE DERIVATIVES AND A THERAPEUTIC AGENT
  申请人：PTC Therapeutics, Inc.

  公开号：EP2416772A1

  公开（公告）日：2012-02-15
• US9198907B2
  申请人：——

  公开号：US9198907B2

  公开（公告）日：2015-12-01
• US9593108B2
  申请人：——

  公开号：US9593108B2

  公开（公告）日：2017-03-14
• [EN] COMBINATIONS OF A HCV INHIBITOR SUCH AS BICYCLIC PYRROLE DERIVATIVES AND A THERAPEUTIC AGENT<br/>[FR] ASSOCIATIONS D'UN INHIBITEUR DU VIRUS DE L'HÉPATITE C (VHC), TELS DES DÉRIVÉS PYRROLIQUES BICYCLIQUES, ET D'UN AGENT THÉRAPEUTIQUE
  申请人：SCHERING CORP

  公开号：WO2010117936A1

  公开（公告）日：2010-10-14

  The present invention is directed to a combination product for treating or ameliorating hepatitis C virus (HCV) infection or disorders or symptoms associated therewith in a subject in need thereof comprising, a HCV inhibitor and one or more therapeutic agents selected from either or both a HCV protease inhibitor and one or more different therapeutic agents administered in combination in an effective amount to the subject.